无并发症型B型主动脉夹层中时间就是主动脉
本文为叙述性综述,检索PubMed与Scopus等多个电子数据库,评估不同时间点行胸主动脉腔内修复术(TEVAR)治疗无并发症型B型主动脉夹层(uTBAD)的安全性、疗效与结局。综述认为超急性期(<24小时)TEVAR围手术期风险过高而不被鼓励,亚急性期(14-90天)为最佳治疗窗口,慢性期(>90天)结局较差。
要点
- 超急性期(<24小时)TEVAR围手术期风险过高,不被鼓励。
- 亚急性期(14-90天)兼顾手术安全性与疗效,为最佳治疗窗口。
- 慢性期(>90天)TEVAR再干预率更高、并发症更多、主动脉重塑有限。
核心结论
- 分析的各研究结果一致表明,亚急性期在降低手术风险与获得良好长期结局之间提供了最佳组合。
- 然而,需要更强的证据来完善时机策略。
研究设计与样本
- 叙述性综述,检索PubMed与Scopus等多个电子数据库,综合关于uTBAD中TEVAR时机的证据。
主要发现
- 超急性期(<24小时)TEVAR与过高的围手术期风险相关,因此不被鼓励。
- 急性期(1-14天)TEVAR可能带来主动脉重塑获益,但早期并发症与再干预率偏高。
- 亚急性期(14-90天)被一致认为是最佳治疗窗口,在手术安全性与疗效之间取得平衡,研究报告其死亡率、并发症与主动脉重塑结局更优。
- 慢性期(>90天)TEVAR虽在疾病进展时有时必要,但结局较差,包括再干预率更高、并发症更多,且相较亚急性期主动脉重塑有限。
关键数值与推荐
- 超急性期TEVAR:<24小时,围手术期风险过高,不被鼓励。
- 急性期TEVAR:1-14天,可能获益于主动脉重塑,但早期并发症与再干预率偏高。
- 亚急性期TEVAR:14-90天,为最佳治疗窗口。
- 慢性期TEVAR:>90天,再干预率更高、并发症更多、主动脉重塑有限。
临床怎么用
- 国际指南认为,通过最佳药物治疗优化心血管控制仍是无并发症型B型主动脉夹层(uTBAD)治疗的金标准。
- 综述指出亚急性期(14-90天)为TEVAR的最佳治疗窗口,但需要更强证据来完善时机策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although cardiovascular control optimization through best medical therapy remains the gold standard of treatment for uncomplicated type B aortic dissection (uTBAD) according to international guidelines, thoracic endovascular aortic repair (TEVAR) has increasingly emerged as a viable and appealing treatment option due to its potential to induce favorable aortic remodeling and improve long-term outcomes. However, the optimal timing of TEVAR in uTBAD remains a subject of debate. This narrative review aims at evaluating safety, efficacy, and outcomes of TEVAR at different time points of the disease history. METHODS: We conducted a comprehensive literature review across multiple electronic databases, including PubMed and Scopus, to synthesize research evidence on the timing of TEVAR in uTBAD. RESULTS: Hyperacute-phase TEVAR (<24 hours) is associated with prohibitive periprocedural risks and is thus discouraged. Acute-phase TEVAR (1-14 days) may provide benefits in aortic remodeling but it is burdened by rather elevated rates of early complications and reinterventions. The subacute phase (14-90 days) is consistently identified as the optimal therapeutic window, balancing procedural safety and efficacy, with studies reporting superior outcomes in terms of mortality, complications, and aortic remodeling. Chronic-phase TEVAR (>90 days), although sometimes necessary in cases of disease progression, is associated with poorer outcomes, including higher rates of reintervention, complications, and limited aortic remodeling with respect to the subacute phase. CONCLUSION: The consistent findings across the studies analyzed indicate that the subacute phase offers the best combination of reduced procedural risks and favorable long-term outcomes. However, stronger evidence is needed to refine timing strategies.
引用
- Civilini E, Pascucci MG, Jubouri M, et al. Time is Aorta in Uncomplicated Type B Aortic Dissection. Ann Vasc Surg. 2025. PMID: 39892830. doi:10.1016/j.avsg.2025.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。